Literature DB >> 23636440

[Atrial fibrillation: current recommendations for diagnosis and treatment].

P Kirchhof1.   

Abstract

Atrial fibrillation (AF) is by far the most common arrhythmia. It occurs more often with increasing age. Patients with AF almost always require oral anticoagulants and a rate-control treatment. In addition, other cardiovascular diseases must also be carefully treated in order to reduce the risks of cardiovascular complications from AF. Most patients profit from rate-control treatment with drugs that slow the conduction of the electrical impulse through the AV node. The aim is a resting heart rate of 100-110/min. If patients suffer from AF whilst on optimal rate control therapy, rhythm-control treatment with antiarrhythmic drugs, cardioversion or catheter ablation is indicated. The choice of the rhythm-control therapy should be made based on safety considerations. Whether achieving sinus rhythm beyond improvement of symptoms improves the prognosis of AF is tested in ongoing trials.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23636440     DOI: 10.1007/s00108-013-3271-2

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  29 in total

1.  A novel, simple scale for assessing the symptom severity of atrial fibrillation at the bedside: the CCS-SAF scale.

Authors:  Paul Dorian; Suzan S Cvitkovic; Charles R Kerr; Eugene Crystal; Anne M Gillis; Peter G Guerra; L Brent Mitchell; Denis Roy; Allan C Skanes; D George Wyse
Journal:  Can J Cardiol       Date:  2006-04       Impact factor: 5.223

2.  "Cardioversion" of atrial fibrillation. A report on the treatment of 65 episodes in 50 patients.

Authors:  B LOWN; M G PERLROTH; S KAIDBEY; T ABE; D E HARKEN
Journal:  N Engl J Med       Date:  1963-08-15       Impact factor: 91.245

Review 3.  Predictable and less predictable unwanted cardiac drugs effects: individual pre-disposition and transient precipitating factors.

Authors:  Larissa Fabritz; Paulus Kirchhof
Journal:  Basic Clin Pharmacol Toxicol       Date:  2010-03       Impact factor: 4.080

4.  A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA).

Authors:  Paulus Kirchhof; Gerold Mönnig; Kristina Wasmer; Achim Heinecke; Günter Breithardt; Lars Eckardt; Dirk Böcker
Journal:  Eur Heart J       Date:  2005-02-25       Impact factor: 29.983

5.  Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society.

Authors:  Paulus Kirchhof; Anne B Curtis; Allan C Skanes; Anne M Gillis; L Samuel Wann; A John Camm
Journal:  Eur Heart J       Date:  2013-01-25       Impact factor: 29.983

Review 6.  Flecainide acetate for the treatment of atrial and ventricular arrhythmias.

Authors:  Stavros Apostolakis; Michael Oeff; Ulrich Tebbe; Larissa Fabritz; Günter Breithardt; Paulus Kirchhof
Journal:  Expert Opin Pharmacother       Date:  2013-01-07       Impact factor: 3.889

7.  Subclinical atrial fibrillation and the risk of stroke.

Authors:  Jeff S Healey; Stuart J Connolly; Michael R Gold; Carsten W Israel; Isabelle C Van Gelder; Alessandro Capucci; C P Lau; Eric Fain; Sean Yang; Christophe Bailleul; Carlos A Morillo; Mark Carlson; Ellison Themeles; Elizabeth S Kaufman; Stefan H Hohnloser
Journal:  N Engl J Med       Date:  2012-01-12       Impact factor: 91.245

8.  Apixaban in patients with atrial fibrillation.

Authors:  Stuart J Connolly; John Eikelboom; Campbell Joyner; Hans-Christoph Diener; Robert Hart; Sergey Golitsyn; Greg Flaker; Alvaro Avezum; Stefan H Hohnloser; Rafael Diaz; Mario Talajic; Jun Zhu; Prem Pais; Andrzej Budaj; Alexander Parkhomenko; Petr Jansky; Patrick Commerford; Ru San Tan; Kui-Hian Sim; Basil S Lewis; Walter Van Mieghem; Gregory Y H Lip; Jae Hyung Kim; Fernando Lanas-Zanetti; Antonio Gonzalez-Hermosillo; Antonio L Dans; Muhammad Munawar; Martin O'Donnell; John Lawrence; Gayle Lewis; Rizwan Afzal; Salim Yusuf
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

9.  Prevalence of unknown atrial fibrillation in patients with risk factors.

Authors:  Alexander Samol; Markus Masin; Reinhold Gellner; Britta Otte; Hermann-Joseph Pavenstädt; Erich Bernd Ringelstein; Holger Reinecke; Johannes Waltenberger; Paulus Kirchhof
Journal:  Europace       Date:  2012-12-20       Impact factor: 5.214

10.  Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial.

Authors:  Sheba Ahmed; Michiel Rienstra; Harry J G M Crijns; Thera P Links; Ans C P Wiesfeld; Hans L Hillege; Hans A Bosker; Dirk J A Lok; Dirk J Van Veldhuisen; Isabelle C Van Gelder
Journal:  JAMA       Date:  2008-10-15       Impact factor: 56.272

View more
  1 in total

1.  Effect of Shen Song Yang Xin Capsule on Myocardial Electrophysiology of Acute Atrial Fibrillation in Canine Model.

Authors:  Kai Zhang; Liang Shi; Hai-Jiao Tang; Long Yang; Xin-Chun Yang
Journal:  Chin Med J (Engl)       Date:  2017-10-20       Impact factor: 2.628

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.